Home Watchlists Portfolios Indices Forex Futures Crypto Comparisons Alerts Screeners Scans Settings

HC Wainwright Reaffirms Buy Rating for Abeona Therapeutics (NASDAQ:ABEO)



  • Source: TechNewsObserver - - Read: 0

    Summary:

     

    Abeona Therapeutics (NASDAQ:ABEO)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Wednesday, October 16th, AnalystRatings.com reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 470.34% from the stock’s previous close.

    Other equities research analysts have also recently issued reports about the company. Maxim Group cut Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 15th. ValuEngine upgraded Abeona Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Royal Bank of Canada lowered their target price on Abeona Therapeutics to $16.00 and set a “posi ...

     

     

    Read Full News: https://technewsobserver.com/news/2019/11/10/abeona-therapeutics-abeo-buy-rating-reiterated-at-hc-wainwright-updated-updated.html


Log in to reply